EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
166Ho-microspheres
90Y-microspheres
Dosimetry
Glass microspheres
Guidelines
Liver cancer
Nuclear medicine
QuiremSpheres®
Resin microspheres
SIR-spheres®
TheraSphere®
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
09
09
2021
accepted:
19
10
2021
pubmed:
12
2
2022
medline:
12
4
2022
entrez:
11
2
2022
Statut:
ppublish
Résumé
Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10-20% of patients are amenable to curative treatment, such as resection or transplant. Liver metastases are most frequently caused by colorectal cancer, which accounts for the second most cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown to be a safe and effective treatment option. The vast potential of personalized dosimetry has also been shown, resulting in markedly increased response rates and overall survival. In a rapidly evolving therapeutic landscape, the role of radioembolization will be subject to changes. Therefore, the decision for radioembolization should be taken by a multidisciplinary tumour board in accordance with the current clinical guidelines. The purpose of this procedure guideline is to assist the nuclear medicine physician in treating and managing patients undergoing radioembolization treatment. PREAMBLE: The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set out in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine involves not only the science but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognised that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.
Identifiants
pubmed: 35146577
doi: 10.1007/s00259-021-05600-z
pii: 10.1007/s00259-021-05600-z
pmc: PMC8940802
doi:
Substances chimiques
Yttrium Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1682-1699Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.
pubmed: 16954555
Salem R, Thurston KG. Radioembolization with (90)yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251–78.
pubmed: 16923973
doi: 10.1097/01.RVI.0000233785.75257.9A
Smits MLJ, et al., Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental & Clinical Cancer Research, 2010. 29.
Westcott MA, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351–64.
pubmed: 28740906
pmcid: 5514171
doi: 10.1016/j.adro.2016.08.003
Pasciak AS, et al. Radioembolization and the dynamic role of (90)Y PET/CT. Front Oncol. 2014;4:38.
pubmed: 24579065
pmcid: 3936249
Lau WY, Li AK. Therapeutic aspects of radioisotopes in hepatobiliary malignancy. Br J Surg. 1992;79(7):711.
pubmed: 1643496
doi: 10.1002/bjs.1800790744
Okuda K, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–28.
pubmed: 2990661
doi: 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353(9160):1253–7.
pubmed: 10217098
doi: 10.1016/S0140-6736(98)09148-X
Lambert B, et al. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328–33.
pubmed: 20683591
doi: 10.1007/s00259-010-1566-2
Leung WT, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35(1):70–3.
pubmed: 8271063
Braat A, et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920–8.
pubmed: 28786008
doi: 10.1007/s00330-017-4998-2
Elschot M, et al. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75.
pubmed: 24819055
doi: 10.1007/s00259-014-2784-9
Dancey JE, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673–81.
pubmed: 11037997
Geschwind JF, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194–205.
pubmed: 15508085
doi: 10.1053/j.gastro.2004.09.034
Goin JE, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195–203.
pubmed: 15713920
doi: 10.1097/01.RVI.0000142602.79459.90
Kennedy AS, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63.
pubmed: 15590187
doi: 10.1016/j.ijrobp.2004.09.004
Lau WY, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40(3):583–92.
pubmed: 9486608
doi: 10.1016/S0360-3016(97)00818-3
Sharma RA, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106.
pubmed: 17369573
doi: 10.1200/JCO.2006.08.7916
Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294–302.
pubmed: 11360053
doi: 10.1016/S1091-255X(01)80051-2
Hogberg J, et al. Increased absorbed liver dose in selective internal radiation therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2(1):10.
pubmed: 26501812
pmcid: 4545624
doi: 10.1186/s40658-015-0113-4
Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl 1):S107–10.
pubmed: 14762849
doi: 10.1002/lt.20036
Garin E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010;37(3):453–61.
pubmed: 19820932
doi: 10.1007/s00259-009-1279-6
Sangro B, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792–800.
pubmed: 16904840
doi: 10.1016/j.ijrobp.2006.05.065
Van Hazel G, et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85.
pubmed: 15499601
doi: 10.1002/jso.20141
Lam MG, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(2):323–9.
pubmed: 23849697
doi: 10.1016/j.ijrobp.2013.05.041
Young JY, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(11):1375–82.
pubmed: 18003987
doi: 10.1016/j.jvir.2007.07.016
Ezziddin S, et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663–9.
pubmed: 22988059
doi: 10.2967/jnumed.112.107482
Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43(2):246–53.
pubmed: 31646375
doi: 10.1007/s00270-019-02350-2
Sangro B, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–46.
pubmed: 18260156
doi: 10.1002/cncr.23339
van Hazel GA, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.
pubmed: 26903575
doi: 10.1200/JCO.2015.66.1181
Mulcahy, M.F., et al., Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol, 2021: p. JCO2101839.
Wasan HS, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.
pubmed: 28781171
pmcid: 5593813
doi: 10.1016/S1470-2045(17)30457-6
Ricke J, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74.
pubmed: 31421157
doi: 10.1016/j.jhep.2019.08.006
Edeline, J., et al., Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol, 2019.
Shady W, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: a comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016;85(6):1224–31.
pubmed: 27161074
pmcid: 5675072
doi: 10.1016/j.ejrad.2016.03.029
Shady W, et al. Surrogate imaging biomarkers of response of colorectal liver metastases after salvage radioembolization using 90Y-loaded resin microspheres. AJR Am J Roentgenol. 2016;207(3):661–70.
pubmed: 27384594
pmcid: 5675077
doi: 10.2214/AJR.15.15202
Fendler WP, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54(8):1202–8.
pubmed: 23729697
doi: 10.2967/jnumed.112.116426
Gulec SA, et al. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38(7):1289–95.
pubmed: 21461737
doi: 10.1007/s00259-011-1758-4
Soydal C, et al. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34(5):501–6.
pubmed: 23478586
doi: 10.1097/MNM.0b013e32835f9427
Zerizer I, et al. The role of early (1)(8)F-FDG PET/CT in prediction of progression-free survival after (9)(0)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39(9):1391–9.
pubmed: 22644713
doi: 10.1007/s00259-012-2149-1
Braat M, et al. Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res. 2017;7(1):2.
pubmed: 28058660
pmcid: 5215993
doi: 10.1186/s13550-016-0248-x
Vilgrain V, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.
pubmed: 29107679
doi: 10.1016/S1470-2045(17)30683-6
Dutton SJ, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.
pubmed: 25011439
pmcid: 4107961
doi: 10.1186/1471-2407-14-497
Gray B, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.
pubmed: 11843249
doi: 10.1023/A:1013569329846
Chow PKH, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.
pubmed: 29498924
doi: 10.1200/JCO.2017.76.0892
Helmberger T, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35.
pubmed: 32959085
doi: 10.1007/s00270-020-02642-y
Schutte K, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer. 2020;9(6):771–86.
pubmed: 33442545
pmcid: 7768116
doi: 10.1159/000510798
Kohler M, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9:1.
doi: 10.3390/jcm9010056
Hunt AP, et al. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur J Pharm Biopharm. 2006;62(1):26–31.
pubmed: 16154332
doi: 10.1016/j.ejpb.2005.06.005
Chiesa C, Maccauro M. (166)Ho microsphere scout dose for more accurate radioembolization treatment planning. Eur J Nucl Med Mol Imaging. 2020;47(4):744–7.
pubmed: 31875243
doi: 10.1007/s00259-019-04617-9
Grosser OS, et al. Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry: influence on the liver-lung shunt. J Nucl Med. 2016;57(6):925–7.
pubmed: 26912438
doi: 10.2967/jnumed.115.169987
Lopez B, et al. Calculation of lung mean dose and quantification of error for (90) Y-microsphere radioembolization using (99m) Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys. 2019;46(9):3929–40.
pubmed: 31063600
doi: 10.1002/mp.13575
Das A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020;47(4):807–15.
pubmed: 31502015
doi: 10.1007/s00259-019-04517-y
Ho S, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–8.
pubmed: 9143467
Salem R, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431–8.
pubmed: 18838878
doi: 10.1097/COC.0b013e318168ef65
Jadoul A, et al. Comparative dosimetry between (99m)Tc-MAA SPECT/CT and (90)Y PET/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):828–37.
pubmed: 31388721
doi: 10.1007/s00259-019-04465-7
Gnesin S, et al. Partition model based Tc-99m-MAA SPECT/CT predictive dosimetry compared with Y-90 TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672–8.
pubmed: 27307346
doi: 10.2967/jnumed.116.173104
Ilhan H, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56(11):1654–60.
pubmed: 26315830
doi: 10.2967/jnumed.115.162685
Wondergem M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294–301.
pubmed: 23749996
doi: 10.2967/jnumed.112.117614
Haste P, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission ct and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28(5):722–30.
pubmed: 28238581
doi: 10.1016/j.jvir.2016.12.1221
Garin E, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.
pubmed: 23613103
pmcid: 3679421
doi: 10.1007/s00259-013-2395-x
Garin E, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255–63.
pubmed: 22302962
doi: 10.2967/jnumed.111.094235
Chiesa C, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55(2):168–97.
pubmed: 21386789
Ho CL, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET/CT and posttreatment (90)Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45(12):2110–21.
pubmed: 29948107
doi: 10.1007/s00259-018-4064-6
Hermann AL, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673–84.
pubmed: 32602828
doi: 10.1148/radiol.2020191606
Lau WY, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70(5):994–9.
pubmed: 7947110
pmcid: 2033550
doi: 10.1038/bjc.1994.436
Garin, E., et al., Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol, 2020
Smits MLJ, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806.
pubmed: 31399801
doi: 10.1007/s00259-019-04460-y
Salem R, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–704.
pubmed: 31098749
doi: 10.1007/s00259-019-04340-5
Lewandowski RJ, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–8.
pubmed: 29688155
doi: 10.1148/radiol.2018171768
Meiers C, et al. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol. 2018;9(2):311–5.
pubmed: 29755770
pmcid: 5934149
doi: 10.21037/jgo.2017.11.02
Padia SA, et al. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067–73.
pubmed: 24837982
doi: 10.1016/j.jvir.2014.03.030
Biederman DM, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30–7 e2.
pubmed: 29169782
doi: 10.1016/j.jvir.2017.08.026
Garin E, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.
pubmed: 25678490
doi: 10.2967/jnumed.114.145177
Konijnenberg M., et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021:48(1);67–72
Ho S, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947–52
Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718–38.
pubmed: 26112387
doi: 10.1007/s00259-015-3068-8
Chiesa C, Bardies M, Zaidi H. Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy. Med Phys. 2019;46(12):5403–6.
pubmed: 31584697
doi: 10.1002/mp.13851
Dewaraja YK, et al. Prediction of tumor control in (90)Y radioembolization by logit models with PET/CT-based dose metrics. J Nucl Med. 2020;61(1):104–11.
pubmed: 31147404
pmcid: 6954459
doi: 10.2967/jnumed.119.226472
Kappadath SC, et al. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451–61.
pubmed: 30191875
doi: 10.1016/j.ijrobp.2018.05.062
Chiesa, C., et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre- and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021:8(1);77
Roosen, J., et al., To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging, 2021.
Salem R, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021.
Lewandowski RJ, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99–105.
pubmed: 27103352
doi: 10.1002/jso.24269
Palard X, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392–401.
pubmed: 29177870
doi: 10.1007/s00259-017-3845-7
Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018–32.
pubmed: 32451604
doi: 10.1007/s00259-020-04845-4
Shepherd FA, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70(9):2250–4.
pubmed: 1327493
doi: 10.1002/1097-0142(19921101)70:9<2250::AID-CNCR2820700906>3.0.CO;2-4
Bourien H, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46(3):669–76.
pubmed: 30374530
doi: 10.1007/s00259-018-4199-5
Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.
pubmed: 23602420
pmcid: 3800023
doi: 10.1016/j.jvir.2013.02.031
Padia SA, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172–8.
pubmed: 32944980
doi: 10.1002/jso.26223
Alsultan, A.A., et al., Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases. J Nucl Med, 2021.
Lewandowski RJ, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1861–9.
pubmed: 24906565
doi: 10.1007/s00259-014-2799-2
Levillain, H., et al., International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging, 2021
Levillain H, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–9.
pubmed: 31324943
doi: 10.1007/s00259-019-04427-z
van den Hoven AF, et al. Insights into the dose-response relationship of radioembolization with resin 90y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9.
pubmed: 26912436
doi: 10.2967/jnumed.115.166942
Bastiaannet R, et al. First evidence for a dose-response relationship in patients treated with (166)Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608–12.
pubmed: 31601696
doi: 10.2967/jnumed.119.232751
van Roekel C, et al. Dose-effect relationships of (166)Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272–9.
pubmed: 32591491
doi: 10.2967/jnumed.120.243832
Vauthey JN, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233–40.
pubmed: 11910568
doi: 10.1053/jlts.2002.31654
Ahmadzadehfar H, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. EJNMMI Res. 2015;5(1):54.
pubmed: 26463848
pmcid: 4604161
doi: 10.1186/s13550-015-0133-z
Giammarile F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–406.
pubmed: 21494856
doi: 10.1007/s00259-011-1812-2
Lhommel R, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37(9):1654–62.
pubmed: 20422185
doi: 10.1007/s00259-010-1470-9
Selwyn RG, et al. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot. 2007;65(3):318–27.
pubmed: 17045483
doi: 10.1016/j.apradiso.2006.08.009
Kesim S, et al. Unexpected radiation pneumonitis after SIRT with significant decrease in DLCO with internal radiation exposure: a case report. BMC Med Imaging. 2020;20(1):52.
pubmed: 32429910
pmcid: 7236282
doi: 10.1186/s12880-020-00452-9
Auditore L, et al. Monte Carlo (90)Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol. 2020;65(23):235014.
pubmed: 33245055
doi: 10.1088/1361-6560/abbc80
Scott NP, McGowan DR. Optimising quantitative (90)Y PET imaging: an investigation into the effects of scan length and Bayesian penalised likelihood reconstruction. EJNMMI Res. 2019;9(1):40.
pubmed: 31076913
pmcid: 6510762
doi: 10.1186/s13550-019-0512-y
Elschot M, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.
pubmed: 22073149
pmcid: 3207835
doi: 10.1371/journal.pone.0026174
van de Maat GH, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23(3):827–35.
pubmed: 23014797
doi: 10.1007/s00330-012-2648-2
John, L., Discharge of patients undergoing treatment with radioactive substances, A.R.P.a.N.S. Agency, Editor. 2002: Australia
Prince JF, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol. 2014;25(12):1956–1963e1.
pubmed: 25311966
doi: 10.1016/j.jvir.2014.09.003
Laffont S, et al. Occupational radiation exposure of medical staff performing (9)(0)Y-loaded microsphere radioembolization. Eur J Nucl Med Mol Imaging. 2016;43(5):824–31.
pubmed: 26686335
doi: 10.1007/s00259-015-3277-1
Taleb J, et al. Radiation dose measurements for staff members involved in holmium-166 preclinical trial. Radiat Meas. 2013;58:75–8.
doi: 10.1016/j.radmeas.2013.08.007
Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209–11.
pubmed: 16818957
Metyko J, et al. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management. Health Phys. 2012;103(5 Suppl 3):S204–8.
pubmed: 23026974
doi: 10.1097/HP.0b013e31826566f0
Elsayed M, et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med. 2020;45(2):100–4.
pubmed: 31876805
doi: 10.1097/RLU.0000000000002828
Lam MG, et al. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36(5):1320–8.
pubmed: 23354961
doi: 10.1007/s00270-013-0547-9
Masthoff M, et al. Repeated radioembolization in advanced liver cancer. Ann Transl Med. 2020;8(17):1055.
pubmed: 33145274
pmcid: 7575953
doi: 10.21037/atm-20-2658
Zarva A, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55(3):360–6.
pubmed: 24516256
doi: 10.2967/jnumed.113.127662
Prajapati HJ, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965–73.
pubmed: 23223331
doi: 10.1093/annonc/mds605
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
pubmed: 20175033
doi: 10.1055/s-0030-1247132
Shim JH, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262(2):708–18.
pubmed: 22187634
doi: 10.1148/radiol.11110282
Gillmore R, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.
pubmed: 21703196
doi: 10.1016/j.jhep.2011.03.007
European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182–236
Pollock RF, et al. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020;20(11):997–1009.
pubmed: 32930618
doi: 10.1080/14737140.2020.1814748
Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413–25.
pubmed: 30603975
doi: 10.1007/s00270-018-2148-0
Memon K, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887–94.
pubmed: 22137020
doi: 10.1016/j.ijrobp.2011.07.041
Beuzit L, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85(8):1445–52.
pubmed: 27423686
doi: 10.1016/j.ejrad.2016.05.020
Camacho JC, et al. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.
pubmed: 24461131
doi: 10.1016/j.jvir.2013.10.056
Akinwande O, et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol. 2016;113(4):443–8.
pubmed: 27060707
doi: 10.1002/jso.24141